Meeting
2019 ASCO Annual Meeting
HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.
Authors
Jason W.D. Hearn
University of Michigan, Ann Arbor, MI
Jason W.D. Hearn , Christopher Sweeney , Nima Almassi , Chad A. Reichard , Chandana A. Reddy , Brian Hobbs , David Frazier Jarrard , Yu-Hui Chen , Robert Dreicer , Jorge A. Garcia , Michael Anthony Carducci , Robert S. DiPaola , Nima Sharifi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT00309985
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5020)
DOI
10.1200/JCO.2019.37.15_suppl.5020
Abstract #
5020
Poster Bd #
132
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
First Author: Susan Halabi
Poster
2015 Genitourinary Cancers Symposium
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
First Author: Jason W.D. Hearn
Poster
2023 ASCO Annual Meeting
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
First Author: Ryan Phillips
Poster
2023 ASCO Annual Meeting
Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.
First Author: Anis Hamid